CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Carvajal from Memorial Sloan-Kettering Cancer Center in New York presented results from a Phase II study with 98 patients randomised to receive an old drug, temozolomide, or selumetinib which inhibits the MEK pathway affected by GNAQ and GNA II gene mutations commonly found in this rare tumour. He discussed findings with Peter Goodwin.
You may also like...
Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation 14 Jan, 2020 Audio Journal of Oncology in Advance – April 15th, 2007 – Bisphosphonates Recommended for Lung Cancer Bone Metastases 15 Apr, 2007 Stage I to III breast cancer: radiation therapy to chest lymph nodes extends life 26 Oct, 2013 Audio Journal of Oncology in Advance – October 1st, 2006 1 Oct, 2006
- Previous story Audio Journal of Oncology with Oncology Times, June 2013
- Next story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014